All In MedTech

Device Trial Radar · NCT07415902

Coronary Artery Drug-Coated Balloon Dilatation Catheter Clinical Trial Protocol

A Retrospective, Multicenter, Post-marketing Clinical Study to Evaluate the Long-term Efficacy and Safety of Coronary Artery Drug-Coated Balloon Dilatation Catheter in the Treatment of In-Stent Restenosis or De Novo Coronary Artery Lesions

Last checked: Nov 20, 2026Latest source record: Feb 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

252

Planned (sponsor's estimate)

Start

Feb 28, 2026

Primary completion

Dec 2028

Study completion Dec 2028

Sponsor

Lead sponsor
DK Medical Technology (Suzhou) Co., Ltd.Not on our public-company list
Sponsor type
Industry
First posted
Feb 17, 2026

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical trial adopts a retrospective, multicenter design with data registered and collected via an Electronic Data Capture (EDC) system. A total of 252 eligible subjects will be enrolled in the trial, who are consecutively selected in accordance with the inclusion and exclusion criteria from 2022 to the end of 2023 in a retrospective manner. Data collection will be conducted at four time points for all enrolled subjects, including the screening period, 6 months (±30 days) after surgery, 12 months (±30 days) after surgery, and 24 months (±60 days) after surgery. Relevant data of retrospective subjects will be obtained by reviewing medical records.

Conditions

  • In-Stent Restenosis or De Novo Coronary Artery Lesions

Interventions

  • Coronary Artery Drug-Coated Balloon Dilatation CatheterDevice

    subjects who have received coronary artery drug-coated balloon dilatation catheter treatment in the selected centers for a period of time since the product's marketing will be screened one by one in accordance with the inclusion and exclusion criteria. During the process, data collection will be conducted by direct medical history collection or reviewing medical records in the medical record system of each center.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. the incidence of Target Lesion Failure (TLF).Time frame: 24 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Second Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.